Long-term follow-up phase I/II trial of NX 1207 in patients with benign prostatic hyperplasia.

Trial Profile

Long-term follow-up phase I/II trial of NX 1207 in patients with benign prostatic hyperplasia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Mar 2011

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Mar 2011 Results from a 7.5-year follow up have been reported in a Nymox media release.
    • 16 Mar 2011 Status changed from active, no longer recruiting to completed.
    • 06 May 2010 Positive 6-year follow-up results reported in a media release from Nymox.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top